Integrated Profiling Delineated KIF18A as a Significant Biomarker Associated with Both Prognostic Outcomes and Immune Response in Pancreatic Cancer
This study confirmed that KIF18A can be used as a marker to predict the prognosis and immunotherapy of PAAD, and it participates in the formation of microtubules in PAAD cells and promotes the malignant behavior of PAAD.
Authors
- Ming Zhang (ORCID: https://orcid.org/0000-0002-4012-3932)
- Yujia Zou
- Zilong Geng (ORCID: https://orcid.org/0009-0009-3140-1214)
- Lei Zhang (ORCID: https://orcid.org/0000-0002-5768-4840)
- Jing Huang (ORCID: https://orcid.org/0000-0002-0103-1226)
- Yin Su
- Yulong Peng
- Kai Nan
Institutions
- Xi'an Honghui Hospital (CN)
- Xi'an Jiaotong University (CN)
Publication Details
- Journal
- ImmunoTargets and Therapy
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/itt.s497284
- Citations
- 2
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09